Find Ospemifene manufacturers, exporters & distributors on PharmaCompass

Ospemifene

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

12 API Suppliers, 8 USDMF, 1 EU WC, 4 NDC API, 4 Listed Suppliers, $ API Reference Price

12 API Suppliers
8 USDMF
1 EU WC
4 NDC API
4 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

2 Intermediates Suppliers

2 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

5 FDF Dossiers, 2 FDA Orange Book, 1 Europe, 1 Canada, 1 Listed Dossiers

5 FDF Dossiers
2 FDA Orange Book
1 Europe
1 Canada
1 Listed Dossiers

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 16 SPI Pharma, 2 Seqens, 3 DKSH, 5 Faran Shimi Pharmaceutical, 1 Boai NKY Pharmaceuticals Ltd, 12 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 1 ACG Worldwide, 3 Actylis, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 19 BASF, 10 Corel Pharma Chem, 5 DFE Pharma, 1 Finar, 7 Gangwal Chemicals, 5 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 31 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 13 Microlex e.U, 2 Nomisma Healthcare, 2 Novo Excipients, 3 Pharmatrans-Sanaq, 5 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 19 Roquette, 7 Seppic, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 2 The Dow Chemical Company, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

76 Fillers, Diluents & Binders, 44 Coating Systems & Additives, 37 Direct Compression, 27 Controlled & Modified Release, 21 Granulation, 20 Thickeners and Stabilizers, 20 Disintegrants & Superdisintegrants, 18 Co-Processed Excipients, 15 Taste Masking, 15 Chewable & Orodispersible Aids, 12 Lubricants & Glidants, 11 Solubilizers, 9 Parenteral, 9 Film Formers & Plasticizers, 7 Topical, 5 Empty Capsules, 5 API Stability Enhancers, 4 Vegetarian Capsules, 4 Coloring Agents, 4 Emulsifying Agents, 2 Rheology Modifiers

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 8 NEWS #PharmaBuzz

media
1 DATA COMPILATION #PharmaFlow
8 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions

globalSalesInformation
1 US Medicaid Prescriptions

MARKET PLACE

9 APIs

marketPlace
9 APIs

PATENTS & EXCLUSIVITIES

18 US Patents

patents
18 US Patents

ANALYTICAL

1 BioAnalytical Methods

otherMethods
1 BioAnalytical Methods

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 4,220

MARKET PLACE

API

FDF

2INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

1DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

8,123,385

Annual Reports (USD Million)

Finished Drug Prices

220 RELATED EXCIPIENT COMPANIES

365EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 128607-22-7, Fc-1271a, Osphena, Senshio, Deamino-hydroxytoremifene, Fc-1271

Molecular Formula

C₂₄H₂₃ClO₂

Molecular Weight

378.9 g/mol

InChI Key

LUMKNAVTFCDUIE-VHXPQNKSSA-N

FDA UNII

B0P231ILBK

Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013.

Ospemifene is an Estrogen Agonist/Antagonist. The mechanism of action of ospemifene is as a Selective Estrogen Receptor Modulator.

1 2D Structure

Ospemifene

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]ethanol

2.1.2 InChI

InChI=1S/C24H23ClO2/c25-16-15-23(19-7-3-1-4-8-19)24(20-9-5-2-6-10-20)21-11-13-22(14-12-21)27-18-17-26/h1-14,26H,15-18H2/b24-23-

2.1.3 InChI Key

LUMKNAVTFCDUIE-VHXPQNKSSA-N

2.1.4 Canonical SMILES

C1=CC=C(C=C1)C(=C(C2=CC=CC=C2)C3=CC=C(C=C3)OCCO)CCCl

2.1.5 Isomeric SMILES

C1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\C3=CC=C(C=C3)OCCO)/CCCl

2.2 Other Identifiers

2.2.1 UNII

B0P231ILBK

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Fc-1271a

2. Osphena

3. Senshio

4. Z-2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol

2.3.2 Depositor-Supplied Synonyms

1. 128607-22-7

2. Fc-1271a

3. Osphena

4. Senshio

5. Deamino-hydroxytoremifene

6. Fc-1271

7. 2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol

8. Tore Iii

9. 2-(p-((z)-4-chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol

10. Ccris 9205

11. (deaminohydroxy) Toremifene

12. B0p231ilbk

13. Chebi:73275

14. Ethanol, 2-[4-[(1z)-4-chloro-1,2-diphenyl-1-buten-1-yl]phenoxy]-

15. Ethanol, 2-[4-[(1z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]-

16. 2-[4-[(z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]ethanol

17. (z)-2-(4-(4-chloro-1,2-diphenylbut-1-en-1-yl)phenoxy)ethan-1-ol

18. 2-{4-[(1z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}ethanol

19. Ospemifene [inn]

20. Unii-b0p231ilbk

21. Ophena

22. Ospemifene [usan:inn:ban]

23. Deaminotoremifene

24. Ethanol, 2-(4-((1z)-4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-

25. Osphena (tn)

26. Deaminohydroxytoremifene

27. Ospemifene [mi]

28. Ospemifene [usan]

29. Ospemifene, Fc-1271a

30. Ospemifene [vandf]

31. Ospemifene [mart.]

32. Ospemifene [who-dd]

33. Ospemifene (inn/usan/ban)

34. Schembl948118

35. Gtpl7349

36. Chembl2105395

37. Ospemifene [orange Book]

38. Hsdb 8281

39. Dtxsid101025426

40. Z-2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol

41. Bcp20981

42. Hy-b0723

43. Zinc1550766

44. Mfcd00871890

45. S4285

46. Akos025401964

47. Ccg-268392

48. Cs-5961

49. Db04938

50. Ncgc00386347-01

51. Ac-27645

52. O0441

53. Sw219657-1

54. A14261

55. D08958

56. J-005613

57. Q7107372

58. Z-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)-phenoxy]-ethanol

59. 2-[4-[(z)-4-chloro-1,2-di(phenyl)but-1-enyl]phenoxy]ethanol

2.4 Create Date

2005-08-08

3 Chemical and Physical Properties

Molecular Formula	C₂₄H₂₃ClO₂
Molecular Weight	378.9 g/mol
XLogP3	6.5
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	2
Rotatable Bond Count	8
Exact Mass	378.1386577 g/mol
Monoisotopic Mass	378.1386577 g/mol
Topological Polar Surface Area	29.5 Å²
Heavy Atom Count	27
Formal Charge	0
Complexity	441
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	1
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Information

1 of 2
Drug Name	Osphena
PubMed Health	Ospemifene (By mouth)
Drug Classes	Endocrine-Metabolic Agent
Drug Label	OSPHENA is anestrogen agonist/antagonist.The chemical structure of ospemifene is shown in Figure 1.Figure 1: Chemical structureThe chemical designation is Z-2-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy]ethanol, and has the empirical formula C24H...
Active Ingredient	Ospemifene
Dosage Form	Tablet
Route	Oral
Strength	60mg
Market Status	Prescription
Company	Shionogi

2 of 2
Drug Name	Osphena
PubMed Health	Ospemifene (By mouth)
Drug Classes	Endocrine-Metabolic Agent
Drug Label	OSPHENA is anestrogen agonist/antagonist.The chemical structure of ospemifene is shown in Figure 1.Figure 1: Chemical structureThe chemical designation is Z-2-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy]ethanol, and has the empirical formula C24H...
Active Ingredient	Ospemifene
Dosage Form	Tablet
Route	Oral
Strength	60mg
Market Status	Prescription
Company	Shionogi

4.2 Therapeutic Uses

/CLINICAL TRIALS/ ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. The Web site is maintained by the National Library of Medicine (NLM) and the National Institutes of Health (NIH). Each ClinicalTrials.gov record presents summary information about a study protocol and includes the following: Disease or condition; Intervention (for example, the medical product, behavior, or procedure being studied); Title, description, and design of the study; Requirements for participation (eligibility criteria); Locations where the study is being conducted; Contact information for the study locations; and Links to relevant information on other health Web sites, such as NLM's MedlinePlus for patient health information and PubMed for citations and abstracts for scholarly articles in the field of medicine. Ospemifene is included in the database.

NIH/NLM; ClinicalTrials.Gov. Available from, as of September 30, 2015: https://clinicaltrials.gov/search/intervention=ospemifene%20OR%20Fc-1271

Osphena is indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. /Included in US product label/

NIH; DailyMed. Current Medication Information for Osphena (Ospemifene) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8462d6ab-e3cd-4efa-a360-75bf8f917287

4.3 Drug Warning

/BOX WARNING/ There is a reported increased risk of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) who received daily oral conjugated estrogens (CE) (0.625 mg)-alone therapy over 7.1 years as part of the Women's Health Initiative (WHI). In the clinical trials for Osphena (duration of treatment up to 15 months), the incidence rates of thromboembolic and hemorrhagic stroke were 0.72 and 1.45 per thousand women, respectively in Osphena 60 mg treatment group and 1.04 and 0 in placebo. The incidence of DVT was 1.45 per thousand women in Osphena 60 mg treatment group and 1.04 per thousand women in placebo. Osphena should be prescribed for the shortest duration consistent with treatment goals and risks for the individual woman.

/BOX WARNING/ Osphena is an estrogen agonist/antagonist with tissue selective effects. In the endometrium, Osphena has estrogen agonistic effects. There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy reduces the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed and random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.

/BOX WARNING/ What is the most important information I should know about Osphena? Osphena is a medicine that works like estrogen in the lining of the uterus (womb), but can work differently in other parts of the body. Taking estrogen-alone or Osphena may increase your chance of getting cancer of the lining of the uterus (womb). Vaginal bleeding after menopause may be a warning sign of cancer of the lining of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause. Tell your healthcare provider right away if you have any unusual vaginal bleeding while you are taking Osphena. Osphena may increase your chance of getting strokes and blood clots. You and your healthcare provider should talk regularly about whether you still need treatment with Osphena.

The pharmacokinetics of ospemifene has not been studied in women with severe hepatic impairment (Child-Pugh Class C); therefore, Osphena should not be used in women with severe hepatic impairment.

For more Drug Warnings (Complete) data for Ospemifene (16 total), please visit the HSDB record page.

4.4 Drug Indication

Ospemifene is used for the treatment of moderate to dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.

FDA Label

Senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women.

5 Pharmacology and Biochemistry

5.1 Pharmacology

The half maximal inhibitory concentration (IC50) for estrogen receptor (ER) alpha and beta are 0.8 M and 1.7 M, respectively. Ospemifene has potential uses in the management of osteoporosis in postmenopausal women. It interacts with osteoblasts and osteoclasts in such a way that it reduces bone turnover. It also has potential uses in the prevention of breast cancer. Studies suggest that ospemifene, in a dose-dependent manner, reduces the incidence of tumours.

5.2 FDA Pharmacological Classification

5.2.1 Active Moiety

OSPEMIFENE

5.2.2 FDA UNII

B0P231ILBK

5.2.3 Pharmacological Classes

Selective Estrogen Receptor Modulators [MoA]; Estrogen Agonist/Antagonist [EPC]

5.3 ATC Code

G03XC05

G - Genito urinary system and sex hormones

G03 - Sex hormones and modulators of the genital system

G03X - Other sex hormones and modulators of the genital system

G03XC - Selective estrogen receptor modulators

G03XC05 - Ospemifene

5.4 Absorption, Distribution and Excretion

Absorption

When a single oral dose of ospemifene 60 mg is given to postmenopausal women under fasted conditions, the pharmacokinetic parameters are as follows: Tmax = 2 hours (range of 1 - 8 hours); Cmax = 533 ng/mL; AUC (0-inf) = 4165 nghr/mL. When the same aforementioned dose is given to postmenopausal women under fed conditions, the pharmacokinetic parameters are as follows: Tmax = 2.5 hours (1 - 6 hours); Cmax = 1198 ng/mL; AUC (0-inf) = 7521 nghr/mL. Accumulation occurs following repeated doses. Time to steady state = 9 days. Although the bioavailability of ospemifene has not been formally evaluated, it is expected to have a low bioavailability because of its lipophilic nature.

Route of Elimination

Following an oral administration of ospemifene, approximately 75% and 7% of the dose was excreted in feces and urine, respectively. Less than 0.2% of the ospemifene dose was excreted unchanged in urine.

Volume of Distribution

448 L

Clearance

Total body clearance = 9.16 L/hr.

/MILK/ Human lacatation data is not available, however, the prodrug is rapidly metabolized upon absorption, and this agent is concentrated in the breast milk.

Briggs, G.G., Freeman, R.K., Yaffee, S.J.; Drugs in Pregancy and Lactation Nineth Edition. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, PA. 2011, p. 839

/MILK/ It is not known whether Osphena is excreted in human breast milk. In a nonclinical study, ospemifene was excreted in rat milk and detected at concentrations higher than that in maternal plasma.

Following a single oral administration of Osphena 60 mg tablet in postmenopausal women under fasted condition, peak median serum concentrations was reached at approximately 2 hours (range: 1 to 8 hours) post-dose. Mean ospemifene C max and AUC 0-inf were 533 ng/mL and 4165 ng/hr/mL, respectively. After a single oral administration of Osphena 60 mg tablet in postmenopausal women with a high fat/high calorie (860 kcal) meal, C max was reached at approximately 2.5 hours (range: 1 to 6 hours) post-dose. Mean ospemifene C max and AUC 0-inf were 1198 ng/mL and 7521 ng/hr/mL, respectively. The absolute bioavailability of ospemifene was not evaluated. Ospemifene exhibits less than dose-proportional pharmacokinetics from 25 to 200 mg with ospemifene capsule formulation. Accumulation of ospemifene with respect to AUC 0-inf was approximately 2 after twelve weeks of daily administration. Steady-state was reached after nine days of ospemifene administration. Osphena is highly (>99 percent) bound to serum proteins. The apparent volume of distribution is 448 L. The apparent terminal half-life of ospemifene in postmenopausal women is approximately 26 hours. Following an oral administration of ospemifene, approximately 75% and 7% of the dose was excreted in feces and urine, respectively. Less than 0.2% of the ospemifene dose was excreted unchanged in urine.

5.5 Metabolism/Metabolites

Ospemifene is hepatically metabolized via CYP3A4, CYP2C9, CYP2C19, and CYP2B6. The major metabolite was 4-hydroxyospemifene, 25% of the parent compound will undergo this biotransformation. Other metabolites include 4'-hydroxy-ospemifene, <7% of the parent compound will undergo this biotransformation. In order of decreasing potency, ospemifene was suggested to be a weak inhibitor for CYP2B6, CYP2C9, CYP2C19, CYP2C8, CYP2D6 and CYP3A4.

The objective of these investigations was to determine the possible effects of the novel selective estrogen receptor modulator, ospemifene, on cytochrome P450 (CYP)-mediated drug metabolism. Ospemifene underwent testing for possible effects on CYP enzyme activity in human liver microsomes and in isolated human hepatocytes. Based on the results obtained in vitro, three Phase 1 crossover pharmacokinetic studies were conducted in healthy postmenopausal women to assess the in vivo effects of ospemifene on CYP-mediated drug metabolism. Ospemifene and its main metabolites 4-hydroxyospemifene and 4'-hydroxyospemifene weakly inhibited a number of CYPs (CYP2B6, CYP2C9, CYP2C19, CYP2C8, and CYP2D6) in vitro. However, only CYP2C9 activity was inhibited by 4-hydroxyospemifene at clinically relevant concentrations. Induction of CYPs by ospemifene in cultured human hepatocytes was 2.4-fold or less. The in vivo studies showed that ospemifene did not have significant effects on the areas under the plasma concentration-time curves of the tested CYP substrates warfarin (CYP2C9), bupropion (CYP2B6) and omeprazole (CYP2C19), demonstrating that pretreatment with ospemifene did not alter their metabolism. Therefore, the risk that ospemifene will affect the pharmacokinetics of drugs that are substrates for CYP enzymes is low.

PMID:23880855 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742231 Turpeinen M et al; Int J Mol Sci 14(7): 14064-75 (2013).

Ospemifene and its main metabolites 4-hydroxyospemifene and 4'-hydroxyospemifene weakly inhibited a number of CYPs (CYP2B6, CYP2C9, CYP2C19, CYP2C8, and CYP2D6) in vitro.

PMID:23880855 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742231 Turpeinen M et al; Int J Mol Sci 14(7): 14064-75 (2013).

In vitro experiments with human liver microsomes indicated that ospemifene primarily undergoes metabolism via CYP3A4, CYP2C9 and CYP2C19. The major metabolite was 4-hydroxyospemifene. The apparent total body clearance is 9.16 L/hr using a population approach.

5.6 Biological Half-Life

Terminal half-life = 26 hours .

The apparent terminal half-life of ospemifene in postmenopausal women is approximately 26 hours.

5.7 Mechanism of Action

Ospemifene is a next generation SERM (selective estrogen receptor modulator) that selectively binds to estrogen receptors and either stimulates or blocks estrogen's activity in different tissue types. It has an agonistic effect on the endometrium.

OSPHENA is an estrogen agonist/antagonist with tissue selective effects. Its biological actions are mediated through binding to estrogen receptors. This binding results in activation of estrogenic pathways in some tissues (agonism) and blockade of estrogenic pathways in others (antagonism).

API SUPPLIERS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

[{"dataSource":"API Export","activeIngredients":"OSPEMIFENE","year":"2021","qtr":"Q1","strtotime":1616956200,"product":"OSPEMIFENE","address":"8-3-166\/7\/1, HETERO HOUSE,","city":"HYDERABAD, AP.","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"NAVANA PHARMACEUTICALS LIMITED","customerCountry":"BANGLADESH","quantity":"0.30","actualQuantity":"300","unit":"GMS","unitRateFc":"1.6","totalValueFC":"460.4","currency":"USD","unitRateINR":111.72,"date":"29-Mar-2021","totalValueINR":"33516","totalValueInUsd":"460.4","indian_port":"Vizag-HIPL SEZ","hs_no":"29094990","bill_no":"4000248","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Vizag-HIPL SEZ","supplierAddress":"8-3-166\/7\/1, HETERO HOUSE,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1631557800,"product":"OSPEMIFENE","address":"8-3-166\/7\/1, HETERO HOUSE,","city":"HYDERABAD, AP.","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"INCEPTA PHARMACEUTICALS LTD","customerCountry":"BANGLADESH","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"1312.9","totalValueFC":"1289.6","currency":"USD","unitRateINR":94860,"date":"14-Sep-2021","totalValueINR":"94860","totalValueInUsd":"1289.6","indian_port":"Vizag-HIPL SEZ","hs_no":"29094990","bill_no":"4000707","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Vizag-HIPL SEZ","supplierAddress":"8-3-166\/7\/1, HETERO HOUSE,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1642444200,"product":"OSPEMIFENE","address":"8-3-166\/7\/1, HETERO HOUSE,","city":"HYDERABAD, AP.","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"NAVANA PHARMACEUTICALS LIMITED","customerCountry":"BANGLADESH","quantity":"15.00","actualQuantity":"15","unit":"KGS","unitRateFc":"1495.5","totalValueFC":"22179.2","currency":"USD","unitRateINR":110146.93333333333,"date":"18-Jan-2022","totalValueINR":"1652204","totalValueInUsd":"22179.2","indian_port":"Vizag-HIPL SEZ","hs_no":"29094990","bill_no":"4000035","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Vizag-HIPL SEZ","supplierAddress":"8-3-166\/7\/1, HETERO HOUSE,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1642444200,"product":"OSPEMIFENE","address":"8-3-166\/7\/1, HETERO HOUSE,","city":"HYDERABAD, AP.","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"NUVISTA PHARMA LIMITED","customerCountry":"BANGLADESH","quantity":"12.00","actualQuantity":"12","unit":"KGS","unitRateFc":"1495.3","totalValueFC":"17740.6","currency":"USD","unitRateINR":110129.66666666667,"date":"18-Jan-2022","totalValueINR":"1321556","totalValueInUsd":"17740.6","indian_port":"Vizag-HIPL SEZ","hs_no":"29094990","bill_no":"4000036","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Vizag-HIPL SEZ","supplierAddress":"8-3-166\/7\/1, HETERO HOUSE,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1649097000,"product":"OSPEMIFENE","address":"8-3-166\/7\/1, HETERO HOUSE,","city":"HYDERABAD, AP.","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"NUVISTA PHARMA LIMITED","customerCountry":"BANGLADESH","quantity":"8.00","actualQuantity":"8","unit":"KGS","unitRateFc":"1353.2","totalValueFC":"10790.1","currency":"USD","unitRateINR":101762.5,"date":"05-Apr-2022","totalValueINR":"814100","totalValueInUsd":"10790.1","indian_port":"Vizag-HIPL SEZ","hs_no":"29094990","bill_no":"4000241","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Vizag-HIPL SEZ","supplierAddress":"8-3-166\/7\/1, HETERO HOUSE,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1686508200,"product":"OSPEMIFENE","address":"8-3-166\/7\/1, HETERO HOUSE,","city":"HYDERABAD, AP.","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"NAVANA PHARMACEUTICALS LIMITED","customerCountry":"BANGLADESH","quantity":"15.00","actualQuantity":"15","unit":"KGS","unitRateFc":"1448","totalValueFC":"21588.2","currency":"USD","unitRateINR":118297.8,"date":"12-Jun-2023","totalValueINR":"1774467","totalValueInUsd":"21588.2","indian_port":"Vizag-HIPL SEZ","hs_no":"29094990","bill_no":"4000471","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Vizag-HIPL SEZ","supplierAddress":"8-3-166\/7\/1, HETERO HOUSE,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1689186600,"product":"OSPEMIFENE","address":"8-3-166\/7\/1, HETERO HOUSE,","city":"HYDERABAD, AP.","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"INCEPT PHARMACEUTICALS LTD.","customerCountry":"BANGLADESH","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"1532.8","totalValueFC":"3041.8","currency":"USD","unitRateINR":125002.5,"date":"13-Jul-2023","totalValueINR":"250005","totalValueInUsd":"3041.8","indian_port":"Vizag-HIPL SEZ","hs_no":"29094990","bill_no":"4000560","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Vizag-HIPL SEZ","supplierAddress":"8-3-166\/7\/1, HETERO HOUSE,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1696444200,"product":"OSPEMIFENE","address":"8-3-166\/7\/1, HETERO HOUSE,","city":"HYDERABAD, AP.","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"NUVISTA PHARMA LIMITED","customerCountry":"BANGLADESH","quantity":"15.00","actualQuantity":"15","unit":"KGS","unitRateFc":"1447.8","totalValueFC":"21474.7","currency":"USD","unitRateINR":119155,"date":"05-Oct-2023","totalValueINR":"1787325","totalValueInUsd":"21474.7","indian_port":"Vizag-HIPL SEZ","hs_no":"29094990","bill_no":"4000788","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Vizag-HIPL SEZ","supplierAddress":"8-3-166\/7\/1, HETERO HOUSE,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1722537000,"product":"OSPEMIFENE","address":"PLOT NO.C-24, MNS HOUSE,","city":"HYDERABAD, AP.","supplier":"MAITHRI DRUGS PRIVATE ","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"NOBIS SCIENTIFIC#LAC SANAYI","customerCountry":"TURKEY","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"5500","totalValueFC":"5401.6","currency":"USD","unitRateINR":453075,"date":"02-Aug-2024","totalValueINR":"453075","totalValueInUsd":"5401.6","indian_port":"Hyderabad Air","hs_no":"29094990","bill_no":"2905371","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO.C-24, MNS HOUSE,, HYDERABAD, AP.","customerAddress":""}]

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country	Total Quantity (KGS)	Average Price (USD/KGS)	Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATES SUPPLIERS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Canada

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

Coating Systems & Additives

Direct Compression

Controlled & Modified Release

Granulation

Thickeners and Stabilizers

Disintegrants & Superdisintegrants

Co-Processed Excipients

Taste Masking

Chewable & Orodispersible Aids

Lubricants & Glidants

Solubilizers

Parenteral

Film Formers & Plasticizers

Topical

Empty Capsules

API Stability Enhancers

Vegetarian Capsules

Coloring Agents

Emulsifying Agents

Rheology Modifiers

Digital Content

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

NEWS #PharmaBuzz

Global Sales Information

Do you need Business Intel? Ask us

US Medicaid Prescriptions

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

APIs

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ANALYTICAL

Upload your methods for free, ask us

BioAnalytical Methods

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Market Place

Home

Post Enquiry

Market Place

Find Ospemifene manufacturers, exporters & distributors on PharmaCompass

Ospemifene

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

12 API Suppliers

8 USDMF

1 EU WC

4 NDC API

4 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

INTERMEDIATES

2 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

5 FDF Dossiers

2 FDA Orange Book

1 Europe

1 Canada

1 Listed Dossiers

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc

16 SPI Pharma

2 Seqens

3 DKSH

5 Faran Shimi Pharmaceutical

1 Boai NKY Pharmaceuticals Ltd

12 Gangwal Healthcare

1 Nanjing Well Pharmaceutical

1 Pfanstiehl

1 ACG Worldwide

3 Actylis

6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

19 BASF

10 Corel Pharma Chem

5 DFE Pharma

1 Finar

7 Gangwal Chemicals

5 Ideal Cures Pvt Ltd

4 Ingredion Pharma Solutions

31 Kerry

3 Kima Chemical

6 Lonza Capsugel

13 Microlex e.U

2 Nomisma Healthcare

2 Novo Excipients

3 Pharmatrans-Sanaq

5 Pluviaendo

3 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

19 Roquette

7 Seppic

5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

10 Sigachi Industries

2 The Dow Chemical Company

3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

76 Fillers, Diluents & Binders

44 Coating Systems & Additives

37 Direct Compression

27 Controlled & Modified Release

21 Granulation

20 Thickeners and Stabilizers

20 Disintegrants & Superdisintegrants

18 Co-Processed Excipients

15 Taste Masking

15 Chewable & Orodispersible Aids

12 Lubricants & Glidants

11 Solubilizers

9 Parenteral

9 Film Formers & Plasticizers

7 Topical

5 Empty Capsules

5 API Stability Enhancers

4 Vegetarian Capsules